Tag: Cguard EPS

SIBERIA trial: Positive one-month results for embolic prevention system

InspireMD has announced positive interim results from the SIBERIA trial, an investigator-initiated study of the CGuard embolic prevention system (EPS). The data were presented...

Regulatory and reimbursement approval of CGuard Embolic Prevention System in Australia

It has been announced that the CGuard Embolic Prevention System (InspireMD) has been granted regulatory approval by the Therapeutic Goods Administration (part of the...

Expanded two-year follow-up results from the PARADIGM clinical study using CGuard...

Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, presented the expanded 24-month follow-up results from the...

InspireMD announces expansion of its distribution network for CGuard EPS

InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production...